Open AccessA multicenter, double-blind, randomized phase III trial of ramucirumab plus docetaxel versus placebo plus docetaxel for treatment of Stage IV non-small cell lung cancer after disease progression on or after platinum-based therapy (REVEL): An Indian patient subgroup analysis
Author(s) -
Kumar Prabhash,
DC Doval,
Bharath Rangarajan,
Naresh Somani,
Aarohan Pruthi,
Yulia D’yachkova,
Tarun Puri
Publication year - 2021
Publication title -
cancer research, statistics, and treatment/cancer research, statistics and treatment
Language(s) - English
Resource type - Journals
eISSN - 2590-3233
pISSN - 2590-3225
DOI - 10.4103/crst.crst_159_21
Subject(s) - docetaxel , ramucirumab , medicine , taxane , neutropenia , paclitaxel , lung cancer , oncology , chemotherapy , adverse effect , surgery , cancer , breast cancer